Cover Image
市場調查報告書

奈米醫藥的全球市場(神經科、心血管系統、抗發炎、抗感染疾病、癌症用途) - 產業分析、規模、市場佔有率、成長率、趨勢及預測

Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019

出版商 Transparency Market Research 商品編碼 294638
出版日期 內容資訊 英文 81 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
奈米醫藥的全球市場(神經科、心血管系統、抗發炎、抗感染疾病、癌症用途) - 產業分析、規模、市場佔有率、成長率、趨勢及預測 Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019
出版日期: 2014年01月08日 內容資訊: 英文 81 Pages
簡介

本報告以奈米醫藥全球市場為焦點,分就神經科、心血管系統、抗發炎、抗感染疾病、癌症用途各產品市場區隔,及北美,歐洲,亞太地區,其他地區別來分析·檢驗趨勢,彙整市場轉變及發展性分析·預測的最新資訊,及活躍於該市場的主要企業概要與競爭情形,為您概述為以下內容。

第1章 序

  • 報告內容說明
  • 調查方法
  • 市場區隔

第2章 摘要整理

第3章 奈米醫藥的全球市場概要

  • 市場動態
    • 市場推動要素
      • 支援奈米醫藥的技術的提升
      • 強化了奈米醫藥領域的研究開發的行政支援
      • 高度醫療未滿足需求的存在
      • 投資和醫療保健合資企業的增加
      • 多發的慢性疾病
      • 市場推動要素的影響度分析
  • 阻礙市場要素
    • 未整備的既成架構
    • 高額的相關成本
    • 阻礙市場要素的影響度分析
  • 市場機會
    • 新興市場上醫療未滿足需求的存在
    • 新醫療用途的發現
  • 波特的五力分析:全球奈米醫藥市場
    • 供給者談判力
    • 購買者談判力
    • 新加入廠商者的威脅
    • 替代品的威脅
    • 競爭
  • 市場向心力分析:全球奈米醫藥市場 - 各用途
  • 全球奈米醫藥市場(單位:100萬美元)

第4章 全球奈米醫藥市場 - 各用途

  • 概要
  • 神經科奈米醫藥
  • 心血管系統奈米醫藥
  • 癌症科奈米醫藥
  • 抗發炎奈米醫藥
  • 抗感染疾病奈米醫藥
  • 其他的用途
  • 比較分析:全球奈米醫藥市場 - 各用途(%)

第5章 全球奈米醫藥市場 - 各地區

  • 概要
    • 比較分析:全球奈米醫藥市場 - 各地區(%)
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 建議

  • 針對推動學術性教育·訓練,與教育機關的合作
  • 重要成長領域的識別與優先化

第7章 企業簡介(企業概要,財務概要,產品結構,產業策略,最近的發展)

  • Abbott Laboratories
  • CombiMatrix Corporation
  • Celgene Corporation
  • Mallinckrodt plc.
  • GE Healthcare
  • Johnson & Johnson
  • Merck & Company Inc.
  • Nanosphere, Inc.
  • Pfizer Inc.
  • Sigma-Tau Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

圖表一覽

目錄

This report includes market estimations for nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019.

The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report.

The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world.

The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period.

The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

The global nanomedicine market is categorized into the following segments:

Nanomedicine Market by Application

  • Neurology
  • Cardiovascular
  • Anti-Inflammatory
  • Anti-Infectives
  • Oncology
  • Others

Nanomedicine Market by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Preface

  • 1.1 Report description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Nanomedicine Market Overview

  • 3.1 Market Dynamics
    • 3.1.1 Market Drivers
      • 3.1.1.1 Improvement in technology for nanomedicine
      • 3.1.1.2 Rising government support for research and development in nanomedicine
      • 3.1.1.3 Presence of high unmet medical needs
      • 3.1.1.4 Increase in investment amount and healthcare collaborations
      • 3.1.1.5 High prevalence of chronic diseases
      • 3.1.1.6 Impact Analysis of the Market Drivers
    • 3.1.2 Market Restraints
      • 3.1.2.1 Lack of organized regulatory framework
      • 3.1.2.2 High costs involved
      • 3.1.2.3 Impact Analysis of the Market Restraints
    • 3.1.3 Market Opportunities
      • 3.1.3.1 Presence of unmet medical needs in emerging economies
      • 3.1.3.2 Identification of new medical applications
  • 3.2 Porter's Five Forces Analysis: Global Nanomedicine Market
    • 3.2.1 Bargaining Power of Suppliers
    • 3.2.2 Bargaining Power of Buyers
    • 3.2.3 Threat of New entrants
    • 3.2.4 Threat of Substitutes
    • 3.2.5 Competitive Rivalry
  • 3.3 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
  • 3.4 Global Nanomedicine Market, 2011 - 2019 (USD Million)

Chapter 4 Global Nanomedicine Market, by Applications

  • 4.1 Overview
  • 4.2 Nanomedicine for Neurology
    • 4.2.1 Global Nanomedicine for Neurology Market, 2011 - 2019 (USD Billion)
    • 4.3 Nanomedicine for Cardiovascular (CVS)
  • 4.3.1 Global Nanomedicine for Cardiovascular Market , 2011 - 2019 (USD Billion)
  • 4.4 Nanomedicine for Oncology
    • 4.4.1 Global Nanomedicine for Oncology Market , 2011 - 2019 (USD Billion)
  • 4.5 Nanomedicine for Anti-inflammatory
    • 4.5.1 Global Nanomedicine for Anti-Inflammatory Market, 2011 - 2019 (USD Billion)
  • 4.6 Nanomedicine for Anti-infectives
    • 4.6.1 Global Nanomedicine for Anti-Infectives Market, 2011 - 2019 (USD Billion)
  • 4.7 Other Applications
    • 4.7.1 Global Nanomedicine Market for Other Applications, 2011 - 2019 (USD Billion)
  • 4.8 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (%)

Chapter 5 Global Nanomedicine Market, by Geography

  • 5.1 Overview
    • 5.1.1 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
  • 5.2 North America
    • 5.2.1 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.3 Europe
    • 5.3.1 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.4 Asia-Pacific
    • 5.4.1 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.5 Rest of the World
    • 5.5.1 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)

Chapter 6 Recommendations

  • 6.1 Collaborating with educational institutions to boost interdisciplinary education and training
  • 6.2 Identifying and prioritizing key growth areas

Chapter 7 Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 CombiMatrix Corporation
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategy
    • 7.2.5 Recent Developments
  • 7.3 Celgene Corporation
    • 7.3.1 Company Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 Mallinckrodt plc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
    • 7.4.5 Recent Developments
  • 7.5 GE Healthcare
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments
  • 7.6 Johnson & Johnson
    • 7.6.1 Company Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Product Portfolio
    • 7.6.4 Business Strategies
    • 7.6.5 Recent Developments
  • 7.7 Merck & Company Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Product Portfolio
    • 7.7.4 Business Strategies
    • 7.7.5 Recent Developments
  • 7.8 Nanosphere, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Overview
    • 7.8.3 Product Portfolio
    • 7.8.4 Business Strategies
    • 7.8.5 Recent Developments
  • 7.9 Pfizer Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Overview
    • 7.9.3 Product Portfolio
    • 7.9.4 Business Strategies
  • 7.10 Sigma-Tau Pharmaceuticals Inc.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Overview
    • 7.10.3 Product Portfolio
    • 7.10.4 Business Strategies
    • 7.10.5 Recent Developments
  • 7.11 Teva Pharmaceutical Industries Ltd.
    • 7.11.1 Company Overview
    • 7.11.2 Financial Overview
    • 7.11.3 Product Portfolio
    • 7.11.4 Business Strategy
    • 7.11.5 Recent Developments
  • 7.12 UCB SA
    • 7.12.1 Company Overview
    • 7.12.2 Financial Overview
    • 7.12.3 Product Portfolio
    • 7.12.4 Business Strategies
    • 7.12.5 Recent Developments

List of Figures

  • FIG. 1 Market Segmentation for the Nanomedicine Market
  • FIG. 2 Global Nanomedicine Market, by Application and Geography, 2012 (USD Billion)
  • FIG. 3 Porter's Five Forces Analysis: Global Nanomedicine Market
  • FIG. 4 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
  • FIG. 5 Global Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 6 Global Nanomedicine for Neurology Market, 2011 - 2019 (USD Billion)
  • FIG. 7 Global Nanomedicine for Cardiovascular Market, 2011 - 2019 (USD Billion)
  • FIG. 8 Global Nanomedicine for Oncology Market, 2011 - 2019 (USD Billion)
  • FIG. 9 Global Nanomedicine for Anti-Inflammatory Market, 2011 - 2019 (USD Billion)
  • FIG. 10 Global Nanomedicine for Anti-Infective Market, 2011 - 2019 (USD Billion)
  • FIG. 11 Global Nanomedicine Market for Other Applications, 2011 - 2019 (USD Billion)
  • FIG. 12 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (Value %)
  • FIG. 13 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
  • FIG. 14 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 15 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 16 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 17 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 18 Abbott Laboratories: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 19 CombiMatrix Corporation: Annual Sales, 2010 - 2012 (USD Million)
  • FIG. 20 Celgene Corporation: Annual Sales, 2010 - 2012 (USD Million)
  • FIG. 21 Covidien Plc.: - Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 22 GE Healthcare: Annual Revenue, 2010-2012 (USD Million)
  • FIG. 23 Johnson & Johnson: Medical Devices and Diagnostic Business Segment, Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 24 Merck & Co. Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 25 Nanosphere Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 26 Pfizer Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 27 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2010-2012 (USD Million)
  • FIG. 28 UCB S.A.: Annual Revenue, 2010 - 2012 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Nanomedicine Market
  • TABLE 2 Impact Analysis of the Market Drivers for the Global Nanomedicine Market
  • TABLE 3 Impact Analysis of the Market Restraints for the Global Nanomedicine Market
  • TABLE 1 Global Nanomedicine Market, by Applications, 2011 -2019 (USD Billion)
  • TABLE 2 Global Nanomedicine Market, by Geography, 2011 - 2019 (USD Billion)
Back to Top